NDAINTRAVENOUSPOWDER
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
6/8 — Strong
CASPOFUNGIN ACETATE (caspofungin acetate) by Fresenius Kabi is [see microbiology ()]. First approved in 2016.
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Caspofungin acetate is an echinocandin antifungal agent administered intravenously as a powder formulation. It is indicated for invasive fungal infections including candidemia, esophageal candidiasis, and aspergillosis in immunocompromised patients. The drug works by inhibiting fungal cell wall synthesis through inhibition of glucan synthase.
$0.819MPart D
Peak6.5 years to LOEProduct is in peak lifecycle stage with stable but modest Part D utilization, suggesting a mature commercial infrastructure with consolidated field presence.
Mechanism of Action
[see Microbiology ()].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)
Started Jan 2008
63 enrolled
Fungal Infection
Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)
Started Mar 2006
131 enrolled
Fungal Infection
Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
Started May 2004
16 enrolled
Fungal Infection
Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
Started Aug 2003
13 enrolled
InfectionUnspecified Adult Solid Tumor, Protocol Specific
Worked on CASPOFUNGIN ACETATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.